Today's Briefing

Track consequential science and health — disease outbreaks and public-health moves, drug approvals and major trial readouts, breakthroughs in biology/energy/space, and the policy around them. Lead with what's new, grounded in primary findings.

Track the fault lines reshaping the world order — active wars and ceasefires, US/China/Russia/EU competition, elections and leadership shifts abroad, and realigning alliances. Lead with what moved this week and what it signals.

Track the AI frontier — major model and product releases, the lab and big-tech race, compute and capex, and AI policy. Separate genuine capability from hype; lead with what actually shipped this week and why it matters.

Track the storylines driving major sports — league races and standings, marquee games and upsets, trades and signings, and the off-field business and controversy. Lead with what changed this week and the narrative it advances.

Track the forces on the US economy and household pressure — inflation, the Fed and rates, jobs, growth, and the cost of living. Lead with the latest data and what it means for where the cycle is headed, not just the number.

Track the consolidation and contestation of power in US federal politics — executive actions, court reversals, and electoral-map fights — and what the pattern signals. Lead with what changed in the past week.

I'm looking for a list of movies and tv shows about technology, computers, the internet, etc. from the 1980s, 1990s and early 2000s. I want to explore how tech, innovation, and the drastic changes the internet and computer brought about were explored in popular culture. Start with the obvious movies (for example The Net) but continue to explore to find more obscure movies and tv shows that might explore these themes.

What is the market for autonomous or AI research tools? There's gemini deep research, google scholar, perplexity. Sacra is another research platform. What do all of these tools do? What are their features? Their value prop? Their core technology? Their data and where does it come from? Who do they sell to? what is the pricing/business model? Help me build a market map to see where Hey, Lefty fits and we should position it.

Track how autonomous vehicles threaten the auto-insurance business model — a novel, mostly-unwritten exposure (only industry blogs and a stray Morningstar note today). As Waymo and Tesla scale driverless miles, who absorbs the liability and what happens to the premium pool insurers depend on? Core entities: AV operators (Waymo/Alphabet, Tesla, Zoox/Amazon, plus the Aurora/trucking angle); the personal-auto insurers most exposed to premium erosion (Progressive, Allstate, GEICO/Berkshire, Root, Kemper); commercial-fleet and reinsurance players; and the liability shift toward product liability on the AV maker. I want to track driverless-mile expansion and safety data, any insurance products AV operators launch or self-insure, auto-insurer earnings commentary on frequency/severity and pricing, regulatory moves on AV liability, and personal-auto premium and combined-ratio trends in filings. Pull prices, filings, and earnings-call quotes for the named insurers and AV operators. Flag any early sign AV adoption is eroding the personal-auto premium pool, and any divergence between insurer guidance and the adoption curve. The thesis: AVs don't just disrupt driving — they hollow out a trillion-dollar premium pool, and the timing is mispriced.

Track who is financially exposed if the AI infrastructure buildout slows — the exposure map nobody has stitched together. The bull case (Nvidia, hyperscaler capex) is covered everywhere; I want the other side: where the spending becomes someone else's revenue and what breaks if it stalls. Core entities: the chip layer (Nvidia, AMD, Broadcom, Marvell, TSMC); the hyperscaler buyers (Microsoft, Amazon, Google, Meta, Oracle) and their capex guidance; the "neocloud" layer (CoreWeave, Nebius, Lambda) and how it's financed; the power/physical buildout (Vertiv, Eaton, Constellation, Vistra); and the debt — who funds data centers with leverage, the vendor-financing loops, and the private-credit exposure. I want to track quarterly capex guidance and revisions, signals about demand sustainability and customer concentration, and the financing structures underneath (debt issuance, SPVs, circular supplier-funds-customer deals). Pull prices, filings, and earnings-call commentary for the named companies; watch credit spreads and rating actions on the leveraged players. Flag any divergence between the spending narrative and the cash flows underneath it. The thesis: the market prices the upside as a basket; the downside is a chain of second-order exposures nobody has mapped — build that map and keep it current.

Track the AI-driven memory/storage cycle — HBM, DRAM, NAND — and whether this upcycle is structurally different or the usual boom that busts. (AI Capex Unwind owns the bust exposure; this is the supply-cycle mechanics the semis crowd trades.) Core entities: Micron/MU, SK Hynix, Samsung and the HBM/DRAM/NAND mix; the demand pull (Nvidia/AMD attach rates, hyperscaler orders); supply signals (capex, wafer starts, the Samsung labor situation, yields); the equipment layer (Lam, Applied, ASML, Entegris). Track contract pricing (TrendForce/DRAMeXchange commentary), HBM allocation and "sold-out" claims, bit-supply guidance, inventory, and earnings commentary on pricing power. Flag where pricing/allocation diverges from the "permanently sold out" story, and the classic late-cycle tell (everyone adds capacity at once). The thesis: memory is tech's most violent cycle and AI supercharged it — call the turn, don't ride the narrative.

Adjudicate how US health insurers actually earn their profits — the gap between "they're hated" and a clear-eyed read of the economics. Stay analytical and grounded in the filings. Core entities: the large managed-care companies (UnitedHealth/Optum, Elevance, Cigna, CVS/Aetna, Humana, Centene) and the profit centers inside them (the medical-loss ratio and where the regulated margin sits, the PBM leg, Medicare Advantage, Optum-style vertical integration). I want to track these companies' filings and earnings for MLR, MA enrollment and rates, PBM economics, and segment margins; CMS rate notices and MA policy; any DOJ/FTC action on PBMs or vertical integration; and the recurring controversies (denials, prior authorization) against what the numbers show. Pull prices, filings, and earnings-call quotes for the named insurers. Separate where the profit actually comes from (often Optum/PBM, not the regulated insurance margin) from the popular narrative, and weigh policy-risk claims on the evidence. Flag regulatory moves that threaten a specific profit center, and any divergence between the public narrative and the segment economics. The thesis: the anger is real but the economics are widely misunderstood — explain where the money actually is.

Adjudicate how much institutional and private-equity ownership of single-family homes actually affects prices and rents — a debate that's rigorous but polarized (Cato/industry vs tenant-advocacy) with no neutral read. Core entities: the large SFR owners and operators (Invitation Homes, American Homes 4 Rent, Progress Residential/Pretium, Tricon, Blackstone); build-to-rent developers; and the markets where concentration is highest (Atlanta, Phoenix, Sun Belt metros). I want to track these companies' filings and earnings for portfolio size, rent growth, occupancy, and acquisition pace; the actual share of purchases that are institutional (Redfin/CoreLogic data, John Burns); academic and think-tank studies on the price/rent impact and their methodologies; and any state/federal legislation targeting institutional ownership. Pull prices, filings, and the relevant housing series. Weigh the competing studies on their methods, not their politics, and say what the evidence actually supports. Flag new data that shifts the answer, and where claims outrun the evidence on either side. The thesis: everyone has a position and no one has a neutral read — be the neutral read, grounded in the operators' own numbers.

Track how the AI economy is splitting US metros apart — concentrating wealth, jobs, and housing demand in a handful of winners while office and commercial real estate bifurcates. The pieces are being noticed but no one has stitched the cross-market read. Core entities: metro winners vs laggards (SF/San Jose, Austin, Seattle vs older office-heavy cities); office/CRE exposure (SL Green, Boston Properties, Vornado; the CMBS market and regional-bank CRE books); residential exposure (homebuilders and for-sale/rental markets in AI-boom metros); and the data-center geography pulling investment into specific counties. I want to track CRE fundamentals by metro (office vacancy, CMBS delinquency, regional-bank CRE concentration), home-price and rent divergence across metros (Case-Shiller, Zillow/Redfin commentary), migration and job-posting data, and REIT/bank earnings commentary on geographic divergence. Pull relevant prices, filings, and FRED regional series. Flag metros where office collapse and housing bifurcation happen at once, and any divergence between national averages and the metro-level reality. The thesis: "the US housing/CRE market" is now several diverging markets — the AI map is the dividing line.

Track whether the public "space economy" — about to be repriced by the SpaceX IPO (~June 12) — is a real investable thesis or momentum, and where the read-through actually lands. Core entities: SpaceX (its IPO valuation + Starlink unit economics) and the public comps it will re-rate (Rocket Lab/RKLB, AST SpaceMobile/ASTS, Intuitive Machines, Planet, Redwire, Iridium, Globalstar), split across launch / satellite-services / defense-space; plus the eVTOL adjacency the same crowd lumps in (Joby, Archer). Track the S-1 and how comps re-rate against the SpaceX mark, launch cadence and contract/defense backlog, Starlink subscriber/revenue disclosures, and dilution/cash-burn in the small-caps. Flag where a comp's price is just tracking SpaceX sentiment vs its own fundamentals, and the burn/dilution risk the hype obscures. The thesis: the IPO will drag a basket of loss-making space names with it — separate the few with real revenue from the ones just along for the re-rate.

Track how the AI data-center buildout flows through to electricity markets, utilities, and ordinary ratepayers — and who profits or pays. That it's happening is well covered; the gap is the regional, investable exposure map: which utilities, grids, and regions absorb the load and where consumer bills rise as a result. Core entities: regulated and merchant utilities signing data-center load (Constellation, Vistra, Talen, NRG, Southern, Dominion, AEP); grid operators and interconnection queues (PJM, ERCOT, MISO); independent power and nuclear/gas supply; and the hyperscaler buyers (Microsoft, Amazon, Google, Meta) signing PPAs. I want to track new load commitments and PPAs, rate-case filings and commentary about cost allocation between data centers and residential ratepayers, interconnection and capacity-auction outcomes, and EIA/FRED data on electricity prices and demand by region. Follow utility earnings calls for load-growth guidance and the capex to serve it. Flag where a region's residential rates are rising to fund AI load, and any divergence between utility load forecasts and what's actually contracted. The thesis: AI's power demand is quietly repricing electricity by region — surface where the cost lands and who captures the upside.

Adjudicate whether minimum-wage increases actually accelerate automation and cost jobs — a question with contradictory rigorous studies (EPI/NELP vs Cato/NBER) and no honest synthesis. Where does the credible evidence land, sector by sector? Core ground: the most exposed sectors and their public companies (quick-service restaurants — McDonald's, Chipotle, Wingstop; retail and grocery; warehousing/logistics) and how they discuss labor cost and automation on calls; the kiosk/automation vendors; and the natural experiments (California's $20 fast-food wage, Seattle, state-level increases). I want to track minimum-wage policy changes, employment and hours data in affected sectors (BLS/FRED series), company commentary on labor cost, automation capex, and price increases, and the academic literature with attention to method and funding. Pull relevant series, filings, and earnings quotes. Weigh studies on their designs and say what's actually established versus contested. Flag new natural-experiment evidence (e.g. California fast-food) as it lands, and where a cited study's design doesn't support its headline. The thesis: the literature is weaponized in both directions — separate what's known from what's asserted.

Track which specific companies and sectors actually benefit from reshoring and "friend-shoring" US manufacturing — the investable synthesis that consulting "pros and cons" pieces never produce. Beyond the slogan, where do the capex and the margin actually land? Core entities: factory build-out beneficiaries (industrial REITs; electrical/automation — Eaton, Rockwell, Emerson; construction and engineering); the on-shored capacity itself (semis — TSMC Arizona, Intel, GlobalFoundries; EV/battery plants; pharma/API); the equipment and input suppliers; and the policy money (CHIPS Act, IRA) flowing to named projects. I want to track announced projects and which public companies are actually contracted, capex and order trends in earnings, factory-construction and manufacturing data (Census construction spending, ISM, FRED industrial series), and management commentary about reshoring demand versus hype. Pull prices, filings, and earnings-call quotes for the named names. Flag where reshoring is converting into real revenue versus where it's still a press release, and any divergence between policy dollars announced and projects actually breaking ground. The thesis: reshoring is real but the winners are specific and unobvious — name them and follow the money.

Adjudicate whether a wealth tax is actually administrable and revenue-positive — a polarized debate (Tax Foundation/Cato vs IMF and state-level studies) with no neutral read. Set aside whether it's desirable; can it be implemented, and what would it actually raise? Core ground: the international track record (the European wealth taxes that were repealed — France, Sweden, Germany — and the few that remain — Switzerland, Norway, Spain); US state proposals (California, Washington, Massachusetts) and any federal proposals; valuation and avoidance mechanics (illiquid assets, capital flight, mark-to-market); and the revenue estimates and their assumptions. I want to track legislative proposals and their scoring, the empirical record on capital flight and compliance from countries that tried it, IMF/OECD and think-tank analyses with attention to assumptions, and any litigation or constitutional questions. Weigh the estimates on their methods and say what the implementation record actually shows. Flag new proposals or repeals as they happen, and where a revenue claim rests on a contestable assumption. The thesis: the fight is ideological but the feasibility question is empirical — answer the empirical one.

Adjudicate what the credible evidence actually says about how immigration affects native wages and employment — an adjudication gap, but a politically charged one. Treat it strictly as a labor-economics question and stay scrupulously neutral and evidence-led. Core ground: the canonical studies and their disputes (Card's Mariel boatlift vs Borjas's reanalysis; the National Academies report; recent work on high- vs low-skill effects); the sectors where the effect is most studied (construction, agriculture, hospitality, tech/H-1B); and the data sources (BLS, Census, FRED labor series). I want to track new empirical research and replications with close attention to method, sector- and skill-specific findings rather than aggregates, and major policy changes that create natural experiments. Weigh studies on their designs, distinguish short-run from long-run and skill-group from average effects, and say what's genuinely established versus contested. Flag new credible evidence as it lands, and where a claim generalizes beyond what its study supports. The thesis: the topic is politicized but the labor-economics literature has real answers at the margins — report those, carefully, without taking a side.

Track how higher-for-longer interest rates are working through housing and commercial real estate across countries — the cross-country contagion picture that exists only as scattered single-country academic work, never stitched for investors. Core markets and entities: the most rate-sensitive housing markets (Sweden, Canada, Australia, South Korea, parts of the eurozone) and their banks and homebuilders; global CRE and the cross-border funds/REITs; and banks with concentrated property loan books. I want to track house-price indices and household-debt/variable-rate-mortgage data by country (FRED/OECD/BIS series where available), central-bank rate paths, bank earnings commentary on property-loan losses and provisions, and forced-selling or refinancing-wall signals. Pull relevant prices, filings, and macro series; follow earnings calls of the most exposed banks and property companies. Flag any country tipping from slowdown into genuine bust, and any divergence between official house-price data and what lenders report. The thesis: the rate shock is hitting housing markets on different lags worldwide — map the contagion before it's consensus.

Track the seven largest US tech companies as a group to surface where their fundamentals are diverging — in revenue growth, margin trajectory, capital allocation, and strategic direction. The companies: Apple, Microsoft, Alphabet, Amazon, Nvidia, Meta, and Tesla. For each, I want to track quarterly revenue growth by segment, operating margin trends, capex levels and guidance, and any meaningful shifts in strategic commentary from management. I care especially about relative performance — which of these companies are accelerating versus decelerating, where margins are expanding versus compressing, and how capital allocation priorities are shifting (buybacks versus AI investment versus new business lines). Track analyst estimate revisions across the group to see where consensus expectations are moving. Flag any earnings calls where management commentary suggests a meaningful strategic pivot, a new competitive threat, or a change in the growth trajectory that the market may not be pricing in yet. The thesis here is that the market still trades these as a correlated basket, and the brief should surface the evidence for why that's increasingly wrong.

Track the structural dynamics of the US housing market — supply constraints, demand signals, builder activity, and the policy environment. Core companies: D.R. Horton, Lennar, NVR, Toll Brothers, and Meritage Homes on the homebuilder side. Zillow, Redfin, and CoStar for market data and commentary. I want to follow new home starts, permits, and completions data from Census and HUD. Track existing home inventory levels and months of supply. On earnings calls, follow builder commentary about order trends, cancellation rates, incentive activity (rate buydowns, price cuts), and geographic variation in demand. I also care about mortgage rate developments and any Fed commentary or policy moves that affect housing affordability. Track state and local policy changes around zoning, permitting, and housing supply — especially in high-cost metros. Flag any divergence between what the macro data says and what builders are reporting on their calls.

Track what the major quick-service and fast-casual restaurant companies reveal about the state of the American consumer through their pricing strategies, traffic trends, and earnings commentary. Core companies: McDonald's, Starbucks, Yum Brands (Taco Bell, KFC, Pizza Hut), Restaurant Brands International (Burger King, Popeyes), Chipotle, and Wingstop. I care about same-store sales trends broken down by traffic versus average check — whether growth is coming from real demand or just price increases. Track value menu launches, promotional strategies, and any management commentary about consumer pushback on pricing. Follow franchisee sentiment where available. I also want to track how these companies talk about labor costs, input costs, and margin pressure on their calls. This is a consumer health indicator — flag any signals that suggest trade-down behavior, geographic divergence in demand, or shifts in daypart mix that indicate stress.

Track the resurgence of nuclear energy as a theme across public markets, from uranium supply to reactor development to utility-level adoption. Core companies: Cameco and Kazatomprom on uranium supply. NuScale Power, Oklo, and Nano Nuclear Energy on small modular reactors. Constellation Energy, Vistra, and Southern Company on the utility side. I want to follow regulatory developments — NRC licensing decisions, DOE loan guarantees, and any state or federal policy moves that affect nuclear economics. Track corporate power purchase agreements, especially tech companies contracting directly with nuclear operators for data center power. Follow uranium spot and long-term contract pricing trends. On earnings calls, flag any management commentary about timeline shifts for reactor deployment, cost overruns, or demand from hyperscaler customers. Also track public sentiment and political signals around nuclear — this theme is unusually dependent on regulatory and political momentum.

Track the capital expenditure cycle behind AI infrastructure — who is spending, who is supplying, and where the constraints are. Core companies: Nvidia, AMD, Broadcom, TSMC, Intel Foundry, and Marvell on the semiconductor side. Microsoft, Google, Amazon, Meta, and Oracle on the hyperscaler/capex side. Equinix, Digital Realty, and Vertiv on data center infrastructure. Track quarterly capex guidance and revisions from the hyperscalers, especially commentary about AI-specific spend as a share of total capex. Follow Nvidia's data center revenue trajectory and any signals about demand sustainability, customer concentration, or export restriction impacts. I also want to track the power and energy angle — utilities signing long-term agreements with data center operators, grid capacity concerns, and any companies positioning around nuclear or natural gas for AI power demand. Flag any divergence between management guidance and Street estimates.

Track the commercial and competitive dynamics of GLP-1 receptor agonist drugs and their ripple effects across industries. Core companies to follow: Novo Nordisk (Ozempic, Wegovy), Eli Lilly (Mounjaro, Zepbound), Amgen (MariTide), Viking Therapeutics, and Structure Therapeutics. I care about pipeline developments, pricing and reimbursement changes, formulary decisions by major PBMs and insurers, and any FDA actions on new indications or oral formulations. Beyond pharma, track how GLP-1 adoption is affecting adjacent sectors — food and beverage companies adjusting product strategy, medtech and bariatric device companies seeing volume changes, and insurers revising coverage policies or cost projections. Follow earnings calls and filings for all named companies, and flag any management commentary about competitive positioning, manufacturing capacity, or demand trends.

The daily public-markets brief: distill what's actually moving in the markets you track into the handful of developments a smart, busy investor needs to know about today. Each cycle you're handed a snapshot of the names, sectors, and macro series on your watch — the latest prices and moves, fresh filings and earnings, and the macro prints that just landed. Read it, decide what genuinely matters, and drill into the notable developments for real detail — the actual filing or earnings-call transcript, the load-bearing numbers, exact quotes with the source they came from. Surface: the substantive moves and where the narrative splits (the bull case vs the bear case); notable earnings, guidance changes, filings, M&A, rating moves, and macro surprises; and anything genuinely off-consensus. For each development, name and cite the actual thing — the 10-Q line, the earnings-call quote, the data series and its print — state the real disagreement, then say why it matters for the thesis. Skip generic "the stock moved on earnings" recaps and low-signal noise. Have a point of view — a few well-grounded calls beat a long shallow list of tickers.

Track all enforcement actions, investigations, settlements, fines, and litigation involving AI across the United States and EU. This includes FTC enforcement actions, state attorney general investigations and settlements, EEOC and DOJ actions, SEC enforcement and securities class actions, and private lawsuits. Cover all AI use cases including hiring, lending, insurance, healthcare, advertising, pricing, and consumer-facing AI products. For each action, identify the company involved, the AI system or practice at issue, the legal basis for the action, the outcome or current status, and the penalty or settlement amount. Track emerging patterns in how regulators are interpreting and enforcing existing laws against AI deployments, even where no AI-specific statute exists.

The daily "Oops! All Hacker News" brief: distill what's actually happening on the HN front page into the handful of themes a smart, busy engineer needs to know about today. Each cycle you're handed a cluster map of the current front page (themes, top stories, grounded quotes). Read it, decide what genuinely matters, and drill into the notable stories for real detail — the linked article, the load-bearing comments, exact quotes with their permalinks. Surface: substantive technical debates and where the community splits; notable launches, shutdowns, acquisitions, outages, and security incidents; and anything genuinely surprising. For each theme, name and link the actual thing that was posted, quote the real disagreement, then say why it matters. Skip generic "people discussed X" summaries and low-signal noise. Have a point of view — a few well-grounded themes beat a long shallow list.

Track trends, strategies, and insights relevant to individual stock market investing: macroeconomic signals that affect equity markets, sector rotation patterns, valuation frameworks gaining traction among retail and institutional investors, emerging risks and opportunities in specific sectors, dividend vs. growth strategy debates, and what experienced investors are paying attention to right now. Surface what a self-directed investor needs to understand to make informed decisions — not hot tips, but the context behind the moves.

Track how companies across sectors are adopting autonomous AI agents: enterprise deployments, startup use cases, and SMB experimentation. Monitor what workflows agents are being used for, which frameworks and platforms are gaining traction, what's driving adoption decisions, and what's holding companies back — security concerns, reliability issues, regulatory uncertainty, integration complexity. Surface case studies, survey data, analyst reports, and executive commentary that reveal how the autonomous agent market is actually maturing beyond the hype.

Track the expansion of private credit into mainstream corporate lending: new fund launches and capital raises from Apollo, Ares, Blackstone, and other major players, deals displacing traditional bank syndication, regulatory scrutiny from the SEC and Fed, institutional investor appetite and allocation shifts, risk concentration concerns, default and recovery data, and how private credit terms are evolving as competition intensifies. Surface what an investor or strategist watching the convergence of private credit and corporate finance needs to know to stay ahead of the market.

Track how data residency and cross-border data transfer requirements are evolving across APAC: new laws and amendments by country, enforcement actions, adequacy decisions, guidance from data protection authorities, and how multinational companies are adapting their compliance strategies. Surface what a compliance team managing APAC operations needs to stay current on.

Track how emerging markets in Latin America and Southeast Asia are developing as expansion opportunities for US fintech companies: regulatory changes, licensing developments, local competitor activity, infrastructure investments, mobile payment adoption, and partnership signals. Surface what a strategy team evaluating international expansion needs to watch.

Track the competitive landscape in vertical AI for financial services: new startups entering the space, funding rounds, product launches, bank and insurer partnerships, regulatory approvals, and incumbent responses. Surface what someone mapping this landscape for strategic decisions needs to know.

Track which enterprise software and services companies are most vulnerable to AI-native displacement: legacy vendors losing contracts or market share, AI startups launching competitive products, earnings call language signaling concern, pricing model shifts, and customer migration patterns. Surface what's changing for someone evaluating the enterprise software landscape.

Track the go-to-market strategies AI-native startups are using to displace incumbents: product-led growth tactics, pricing model experiments, open-source plays, community-building approaches, partnership announcements, and launch strategies that are actually working. Surface what's emerging for someone building a GTM playbook.

Track how global regulators are approaching AI liability: new legislation and proposals across jurisdictions, enforcement actions, court decisions, regulatory guidance documents, industry compliance frameworks, and shifts in how liability is being assigned between developers and deployers. Surface emerging trends a legal or risk team at an enterprise need to stay current on.

Track how enterprise buyers are changing their evaluation criteria for B2B software as AI becomes table stakes: new procurement frameworks, shifting expectations around AI features, analyst reports on buying behavior, vendor consolidation trends, and signals from buyer communities and review platforms. Surface what a founder selling to enterprises needs to understand right now.

Track the GLP-1 drug boom and its ripple effects across healthcare: new drug approvals and pipeline updates from Novo Nordisk, Eli Lilly, and competitors, shifts in health insurance coverage and pricing, impact on medical device companies like bariatric surgery and diabetes monitoring, consumer adoption trends, and emerging research on new applications. Surface what an investor watching this space needs to know to stay ahead of the market.